Macitentan in Pulmonary Arterial Hypertension Associated with Congenital Heart Defects

Heart Lung Circ. 2017 Oct;26(10):1006-1007. doi: 10.1016/j.hlc.2017.08.003.

Authors

Julie Wacker¹, Robert G Weintraub²

Affiliations

¹ Department of Cardiology, Royal Children's Hospital, Melbourne, Vic, Australia.
² Department of Cardiology, Royal Children's Hospital, Melbourne, Vic, Australia; Murdoch Children's Research Institute, Melbourne, Vic, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Vic, Australia.

PMID: 28867027
DOI: 10.1016/j.hlc.2017.08.003

No abstract available

Publication types

Editorial

MeSH terms

Endothelin A Receptor Antagonists / therapeutic use
Heart Defects, Congenital / complications*
Humans
Hypertension, Pulmonary* / drug therapy
Hypertension, Pulmonary* / etiology
Hypertension, Pulmonary* / physiopathology
Pulmonary Wedge Pressure / drug effects*
Pyrimidines / therapeutic use*
Sulfonamides / therapeutic use*

Substances

Endothelin A Receptor Antagonists
Pyrimidines
Sulfonamides
macitentan